Article Text

Download PDFPDF
New rheumatoid arthritis genetic factor and C5 serum level
  1. H Mbarek1,
  2. M Kallel-Sellami2,
  3. Y Zerzri2,
  4. K Dawidowicz1,
  5. K Mejri2,
  6. T Bardin3,
  7. B Prum4,
  8. P Dieudé1,5,
  9. E Petit-Teixeira1,
  10. F Cornélis1,6,7,
  11. S Makni8
  1. 1
    GenHotel, EA3886, Laboratoire de Recherche Européen pour la Polyarthrite Rhumatoïde, Évry, France
  2. 2
    Laboratoire d’Immunologie, Hôpital la Rabta, Tunis, Tunisia
  3. 3
    Département de Rhumatologie, Hôpital Lariboisière, Paris, France
  4. 4
    Laboratoire Statistique & Génome, Évry, France
  5. 5
    Département de Rhumatologie, Hôpital Bichat, Paris, France
  6. 6
    Centre Hospitalier Sud Francilien, Corbeil-Essonnes, France
  7. 7
    Unité de Génétique Clinique, Hôpital Lariboisière, Paris, France
  8. 8
    Laboratoire d’Immunologie, Hôpital la Rabta, Tunis, Tunisia
  1. Correspondence to H Mbarek, GenHotel, EA3886, Laboratoire de Recherche Européen pour la Polyarthrite Rhumatoïde, Université Evry-Val d’Essonne – Université Paris 7, 2 Rue Gaston Crémieux, CP 5727, 91057 Evry Genopole Cedex, France; hamdi{at}

Statistics from

There is a significant body of evidence suggesting that complement activation plays an important role in the maintenance of the polyarticular chronic synovitis characteristic of rheumatoid arthritis (RA).1 Recently, a novel RA genetic risk factor was described, involving allelic polymorphisms on the chromosome 9, in the intergenic region between complement factor 5 (C5) and tumour necrosis factor receptor-associated factor 1 (TRAF1) genes.2,3,4 The new genetic factor, detected in RA case-control studies for anti-cyclic citrullinated peptide antibodies and/or rheumatoid factor positive (RF+) RA in North American, Swedish and Dutch populations,2,3 was confirmed by linkage in a …

View Full Text


  • Funding The Association Française des Polyarthritiques, Association Rhumatisme et Travail, the European Union for AutoCure, CMCU (Comité Mixte de Coopération Universitaire Franco-Tunisienne) and La Rabta Hospital, Tunis funded this study.

  • Competing interests None declared.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.